1
|
Meta-analysis of the association between a serotonin transporter 5-HTTLPR polymorphism and smoking cessation. Psychiatr Genet 2016; 26:87-91. [PMID: 26886943 DOI: 10.1097/ypg.0000000000000116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
5-HTTLPR is one of the candidate genes influencing addiction. Recent studies have reported that the 5-HTTLPR genotype is associated with smoking behaviour, but its influence is still controversial. Thus, we reviewed the smoking-cessation outcomes among previously reported studies by comparing the 5-HTTLPR polymorphism. In total, eight studies including 3206 participants for the present meta-analysis were assessed and the S/S, S/L and L/L genotypes were compared with respect to smoking-cessation outcomes. The results of comparing 5-HTTLPR genotypes were as follows: odds ratio (OR)=1.044 and 95% confidence interval (CI)=0.751-1.078 for S/S versus S/L; OR=0.862 and 95% CI=0.690-1.077 for S/L versus L/L; and OR=0.924 and 95% CI=0.689-1.433 for S/S versus L/L. We found no significant association between 5-HTTLPR and smoking cessation, but 5-HTTLPR remains an important smoking-related candidate gene.
Collapse
|
2
|
Li H, Li S, Wang Q, Pan L, Jiang F, Yang X, Zhang N, Han M, Jia C. Association of 5-HTTLPR polymorphism with smoking behaviors: A meta-analysis. Physiol Behav 2015; 152:32-40. [DOI: 10.1016/j.physbeh.2015.09.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Revised: 08/11/2015] [Accepted: 09/08/2015] [Indexed: 10/23/2022]
|
3
|
A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend 2015; 152:1-14. [PMID: 25819021 PMCID: PMC4458176 DOI: 10.1016/j.drugalcdep.2015.03.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Revised: 02/05/2015] [Accepted: 03/02/2015] [Indexed: 12/27/2022]
Abstract
BACKGROUND Substance-related disorders (SRDs) are a major cause of morbidity and mortality worldwide. Family, twin, and adoption studies have demonstrated the substantial heritability of SRDs. To determine the impact of genetic variation on risk for SRD and the response to treatment, researchers have conducted a number of secondary data analyses and quasi-experimental studies that target one or more candidate gene variants. METHODS This review examines studies in which candidate polymorphisms were examined as mediator variables to identify pharmacogenetic effects on subjective responses to drug administration or cues or outcomes of medication trials for SRDs. Efforts to use a meta-analytic approach to quantify these effects are premature because the number of available studies using similar methods and outcomes is limited, so the present review is qualitative. RESULTS Findings from these studies provide preliminary evidence of clinically relevant pharmacogenetic effects. However, independent replication of these findings has been sparse. CONCLUSIONS Although this growing body of literature has produced conflicting results, improved statistical controls may help to clarify the findings. Additionally, the use of empirically derived sub-phenotypes (i.e., which serve to differentiate distinct groups of affected individuals) may also help to identify genetic mediators of pharmacologic response in relation to SRDs. The identification of genetic mediators can inform clinical care both by identifying risk factors for SRDs and predicting adverse events and therapeutic outcomes associated with specific pharmacotherapies.
Collapse
|
4
|
Jones JD, Comer SD, Kranzler HR. The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res 2015; 39:391-402. [PMID: 25703505 PMCID: PMC4348335 DOI: 10.1111/acer.12643] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Accepted: 11/24/2014] [Indexed: 12/16/2022]
Abstract
BACKGROUND Annually, the use and abuse of alcohol contributes to millions of deaths and billions of dollars in societal costs. To determine the impact of genetic variation on the susceptibility to the disorder and its response to treatment, studies have been conducted to assess the contribution of a variety of candidate genetic variants. These variants, which we review here, were chosen based upon their observed or hypothesized functional relevance to alcohol use disorder (AUD) risk or to the mechanism by which medications used to treat the disorder exert their effects. METHODS This qualitative review examines studies in which candidate polymorphisms were tested as moderator variables to identify pharmacogenetic effects on either the subjective response to alcohol or the outcomes of pharmacotherapy. RESULTS Although findings from these studies provide evidence of a number of clinically relevant pharmacogenetic effects, the literature is limited and there are conflicting findings that require resolution. CONCLUSIONS Pharmacogenetic studies of AUD treatment that use greater methodological rigor and better statistical controls, such as corrections for multiple testing, may help to resolve inconsistent findings. These procedures could also lead to the discovery of more robust and clinically meaningful moderator effects. As the field evolves through methodological standardization and the use of larger study samples, pharmacogenetic research has the potential to inform clinical care by enhancing therapeutic effects and personalizing treatments. These efforts may also provide insights into the mechanisms by which medications reduce heavy drinking or promote abstinence in patients with an AUD.
Collapse
Affiliation(s)
- Jermaine D Jones
- Division on Substance Abuse , New York State Psychiatric Institute & Columbia University College of Physicians and Surgeons, New York, New York
| | | | | |
Collapse
|
5
|
Pizzo de Castro MR, Vargas Nunes SO, Guembarovski RL, Ariza CB, Oda JMM, Vargas HO, Piccoli de Melo LG, Watanabe MAE, Berk M, Maes M. STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. J Affect Disord 2015; 172:347-54. [PMID: 25451436 DOI: 10.1016/j.jad.2014.10.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 10/11/2014] [Accepted: 10/11/2014] [Indexed: 11/18/2022]
Abstract
BACKGROUND There is a significant comorbidity between mood disorders and tobacco use disorder (TUD), which may be related to both genetic and environmental factors. Gene variants of the 5-HT transporter, such as STin2 VNTR (a variable number of tandem repeats in the functional serotonin transporter intron 2) may be associated with mood disorders and TUD. AIMS This study aimed to delineate the association between the STin2 genetic polymorphism and comorbid TUD and mood disorders, including depression or bipolar disorder. METHODS We examined the STin2 VNTR polymorphism in never-smokers (n=113); patients with mood disorders without TUD (n=62); patients with TUD without mood disorders (n=90); and patients with both disorders (n=95). RESULTS We found a significant association between the STin2 genetic polymorphism and the above diagnostic groups whereby the STin2.12 allele shows a positive association with comorbid TUD and mood disorders (Odds ratio=3.07, 95% CI=1.41-6.68), while the STin2.10/10 homozygous genotype shows a negative association (Odds ratio=0.34, 95% CI=0.16-0.74). Adjusting for years of education, age, gender, marital status and ethnicity did not change these results, but showed that TUD was associated with lower education levels and less stable relationships, whereas mood disorders were related to female gender. A family history of TUD was significantly associated with TUD in subjects without mood disorders only. CONCLUSIONS The STin2.12 allele is positively and the STin2.10/10 genotype is negatively associated with comorbid TUD and mood disorders, depression or bipolar depression, suggesting that biological endophenotypes, e.g. disorders in serotonin metabolism, may in part underpin this comorbidity.
Collapse
Affiliation(s)
- Márcia Regina Pizzo de Castro
- Center of Approach and Treatment for Smokers, University Hospital, Londrina State University, Campus Universitário, Londrina, Paraná, Brazil.
| | - Sandra Odebrecht Vargas Nunes
- Center of Approach and Treatment for Smokers, University Hospital, Londrina State University, Campus Universitário, Londrina, Paraná, Brazil; Department of Clinical Medicine, Health Sciences Center, Londrina State University, University Hospital, Londrina, Paraná, Brazil
| | - Roberta Losi Guembarovski
- Department of Pathological Sciences, Biological Sciences Centre, Londrina State University, Paraná, Brazil
| | - Carolina Batista Ariza
- Department of Pathological Sciences, Biological Sciences Centre, Londrina State University, Paraná, Brazil
| | - Julie Massayo Maeda Oda
- Department of Pathological Sciences, Biological Sciences Centre, Londrina State University, Paraná, Brazil
| | - Heber Odebrecht Vargas
- Center of Approach and Treatment for Smokers, University Hospital, Londrina State University, Campus Universitário, Londrina, Paraná, Brazil; Department of Clinical Medicine, Health Sciences Center, Londrina State University, University Hospital, Londrina, Paraná, Brazil
| | - Luiz Gustavo Piccoli de Melo
- Center of Approach and Treatment for Smokers, University Hospital, Londrina State University, Campus Universitário, Londrina, Paraná, Brazil
| | | | - Michael Berk
- IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia; Orygen Youth Health Research Centre, Centre for Youth Mental Health, Department of Psychiatry and the Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia; Barwon Health and the Geelong Clinic, Swanston Centre, Geelong, Victoria, Australia
| | - Michael Maes
- IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia; Department of Psychiatry, Chulalongkorn University, Faculty of Medicine, Bangkok, Thailand; Health Sciences Graduate Program, Health Sciences Center, State University of Londrina, Brazil.
| |
Collapse
|
6
|
Pizzo de Castro MR, Maes M, Guembarovski RL, Ariza CB, Reiche EMV, Vargas HO, Vargas MM, de Melo LGP, Dodd S, Berk M, Watanabe MAE, Nunes SOV. SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genet 2014; 15:78. [PMID: 24968820 PMCID: PMC4114164 DOI: 10.1186/1471-2156-15-78] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Accepted: 06/18/2014] [Indexed: 11/26/2022] Open
Abstract
Background The aim of this study was to determine if variable number of tandem repeats (VNTR) in the second intron (STin2) of the serotonin transporter (SLC6A4) gene was associated with tobacco use disorder, successful smoking cessation, or smoking characteristics. In this case–control study, patients with current tobacco use disorder, diagnosed according to DSM IV criteria (n = 185), and never-smokers, diagnosed according to CDC criteria (n = 175), were recruited and received 52 weeks of combined pharmacotherapy and cognitive therapy. Successful smoking cessation was defined as exhaled carbon monoxide < 6 ppm. SLC6A4 gene STin2 VNTR polymorphism was assessed using a Multiplex-PCR-based method. At baseline, participants were evaluated using the Fagerström Test for Nicotine Dependence (FTND) and the ASSIST scale. Results The STin2.12 allele (OR = 2.45; 95% CI = 1.44-4.15, p < 0.001) was associated with an increased risk for tobacco use disorder, while the STin2.10/10 genotype (OR = 0.42; 95% CI 0.25-0.71, p < 0.001) decreased risk. There were no significant associations between tobacco use disorder and the STin2.10 or STin2.9 alleles or the other genotypes (STin2.12/12, 12/10, 12/9, 10/9 or 9/9). There were no significant associations between the STin2 genotypes and alleles and successful smoking cessation, smoking characteristics and increased alcohol or sedative use risk. Conclusions Our results suggest that the STin2.10/10 genotype and STin2.12 allele are associated with tobacco use disorder or nicotine dependence, but not with treatment response or severity of dependence. It is hypothesized that the ST2in.12 allele by modulating the metabolism of serotonin may participate in the pathophysiology of tobacco use disorder or nicotine dependence.
Collapse
Affiliation(s)
| | - Michael Maes
- IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
de Viron S, Malats N, Van der Heyden J, Van Oyen H, Brand A. Environmental and Genomic Factors as well as Interventions Influencing Smoking Cessation: A Systematic Review of Reviews and a Proposed Working Model. Public Health Genomics 2013; 16:159-73. [DOI: 10.1159/000351453] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2012] [Accepted: 04/18/2013] [Indexed: 11/19/2022] Open
|
8
|
Herman AI, Balogh KN. Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse. Subst Abuse Rehabil 2012; 3:49-57. [PMID: 22933845 PMCID: PMC3427938 DOI: 10.2147/sar.s25864] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Serotonin (5-hydroxytryptamine [5-HT]) is an important neurotransmitter implicated in regulating substance-use disorder (SUD) acquisition, maintenance, and recovery. During the past several years, an abundance of research has begun discovering and describing specific 5-HT genetic polymorphisms associated with SUDs. Genetic variations in the 5-HT system, such as SLC6A4, HTR1B, HTR2A, HTR2C, HTR3 (HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E), likely play a role contributing to SUD patient heterogeneity. The 5-HT transporter-linked polymorphic region S allele, located in SLC6A4, has now been modestly associated with alcohol dependence in two large meta-analyses. Additional 5-HT genes may also play a role but have not been extensively investigated. A limited number of SUD treatment studies have included 5-HT gene variation as moderating treatment outcomes, but the results have been equivocal. Future research on 5-HT addiction genetics should adopt whole-genome sequencing technology, utilize large study samples, and collect data from multiple ethnic groups. Together, these methods will build on the work already conducted with the aim of utilizing 5-HT genetics in SUD treatment settings.
Collapse
Affiliation(s)
- Aryeh I Herman
- Department of Psychiatry, VA Connecticut Healthcare/Yale University School of Medicine, West Haven, CT, USA
| | | |
Collapse
|
9
|
Kuepper Y, Wielpuetz C, Alexander N, Mueller E, Grant P, Hennig J. 5-HTTLPR S-allele: a genetic plasticity factor regarding the effects of life events on personality? GENES BRAIN AND BEHAVIOR 2012; 11:643-50. [PMID: 22420614 DOI: 10.1111/j.1601-183x.2012.00783.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Y Kuepper
- Personality Psychology and Individual Differences, Department of Psychology, Justus-Liebig-University Giessen, Giessen, Germany.
| | | | | | | | | | | |
Collapse
|
10
|
Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM. Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. PHARMACOGENOMICS & PERSONALIZED MEDICINE 2012; 5:19-35. [PMID: 23226060 PMCID: PMC3513226 DOI: 10.2147/pgpm.s23462] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/12/2012] [Indexed: 12/15/2022]
Abstract
Serotonin (5-HT) regulates important biological and psychological processes including mood, and may be associated with the development of several psychiatric disorders. An association between psychopathology and genes that regulate 5-HT neurotransmission is a robust area of research. Identification of the genes responsible for the predisposition, development, and pharmacological response of various psychiatric disorders is crucial to the advancement of our understanding of their underlying neurobiology. This review highlights research investigating 5-HT transporter (5-HTTLPR) polymorphism, because studies investigating the impact of the 5-HTTLPR polymorphism have demonstrated significant associations with many psychiatric disorders. Decreased transcriptional activity of the S allele ("risk allele") may be associated with a heightened amygdala response leading to anxiety-related personality traits, major depressive disorder, suicide attempts, and bipolar disorder. By contrast, increased transcriptional activity of the L allele is considered protective for depression but is also associated with completed suicide, nicotine dependence, and attention deficit hyperactivity disorder. For some disorders, such as post-traumatic stress disorder and major depressive disorder, the research suggests that treatment response may vary by allele (such as an enhanced response to serotonin specific reuptake inhibitors in patients with major depressive disorder and post-traumatic stress disorder with L alleles), and for alcohol dependence, the association and treatment for S or L alleles may vary with alcoholic subtype. While some studies suggest that 5-HTTLPR polymorphism can moderate the response to pharmacotherapy, the association between 5-HTTLPR alleles and therapeutic outcomes is inconsistent. The discovery of triallelic 5-HTTLPR alleles (L(A)/L(G)/S) may help to explain some of the conflicting results of many past association studies, while concurrently providing more meaningful data in the future. Studies assessing 5-HTTLPR as the solitary genetic factor contributing to the etiology of psychiatric disorders continue to face the challenges of statistically small effect sizes and limited replication.
Collapse
Affiliation(s)
- George A Kenna
- Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Suriyaprom K, Phonrat B, Chuensumran U, Tungtrongchitr A, Tungtrongchitr R. Association of HTTLPR and 5-HT2A T102C polymorphisms with smoking characteristics and anthropometric profiles of Thai males. GENETICS AND MOLECULAR RESEARCH 2012; 11:4360-9. [DOI: 10.4238/2012.october.15.2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Quaak M, van Schayck CP, Postma DS, Wagena EJ, van Schooten FJ. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012; 107:178-87. [PMID: 21658141 DOI: 10.1111/j.1360-0443.2011.03534.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
AIMS We investigated whether variants in the serotonin transporter gene (SLC6A4) influence smoking cessation rates using antidepressant therapy (i.e. bupropion and nortriptyline). DESIGN Pharmacogenetic (secondary) analysis of a randomized, placebo-controlled efficacy trial of bupropion and nortriptyline for smoking cessation. SETTING Single-centre study, Maastricht University, the Netherlands. PARTICIPANTS A total of 214 of 255 (84%) current daily smokers participating in a randomized controlled efficacy trial. MEASUREMENTS Subjects were genotyped for three functional variants in SLC6A4 (5-HTTLPR, STin2, rs25531). Primary outcome measures were prolonged abstinence from weeks 4-12, 4-26 and 4-52. Secondary outcome measures included 7-day point prevalence abstinence at weeks 4, 12, 26 and 52. FINDINGS Carriers of the 5-HTTLPR high-activity L-variant had higher prolonged cessation rates with bupropion than placebo [odds ratio (OR) = 1.44, 95% confidence interval (CI) = 1.01-2.05, P = 0.04]. Combining the three variants resulted in increased prolonged cessation rates for both bupropion and nortriptyline among carriers of four to five high-activity variants (bupropion: OR = 2.00, 95% CI =1.21-3.29, P = 0.01; nortriptyline: OR = 1.91, 95% CI = 1.02-3.56, P = 0.04). Similar results were found for point prevalence abstinence. CONCLUSIONS Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high-activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels. Prospective studies have to assess if this can improve cessation rates when treatment is targeted at individuals based on their genotypes.
Collapse
Affiliation(s)
- Marieke Quaak
- Department of Toxicology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands
| | | | | | | | | |
Collapse
|
13
|
Abstract
The application of genomic medicine to the treatment of nicotine dependence holds great promise for revitalizing the steady decline in smoking rates witnessed in the USA over the past several decades. This paper examines the current knowledge base concerning the use of biomarkers to guide the selection of nicotine dependence treatments. First, we review the neurobiology of nicotine dependence and present evidence that supports its heritability. We then discuss the various studies of pharmacokinetic and pharmacodynamic genes related to therapeutic response. Current evidence suggests that biomarkers of genetic variability in both nicotine metabolism, referred to as the nicotine metabolite ratio, and dopamine genotypes may be useful for guiding treatment selection for nicotine dependence. Barriers to the translation of this research to clinical practice are discussed, as are directions for future research.
Collapse
Affiliation(s)
- Robert A Schnoll
- Pulmonary, Allergy & Critical Care Division, University of Pennsylvania, Presbyterian Medical Center -1 PHI, 51 N 39th Street, Philadelphia, PA 19104, USA.
| | | |
Collapse
|
14
|
Vasic N, Wolf RC, Wolf N, Connemann BJ, Sosic-Vasic Z. [Pharmacotherapeutic treatment strategies for smoking cessation]. DER NERVENARZT 2011; 82:1449-1459. [PMID: 21207000 DOI: 10.1007/s00115-010-3203-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Regular tobacco smoking occurs in about 35% of the male and 25% of the female German population. Individual attempts to independently quit smoking and to remain abstinent for 1 year have been shown to be successful in less than 5% of cases. This rate can be doubled by means of individual consulting and cognitive-behavioral interventions and additional pharmacological treatment might increase abstinence rates up to 25%. Apart from nicotine substitution (e.g. transdermal, oral and inhalative applications) and bupropion, recent studies have shown beneficial effects of varenicline for smoking cessation and abstinence. Varenicline, a selective partial nicotinergic agonist, has been specifically developed for the purpose of smoking cessation. Currently available data suggest that varenicline is more effective compared to nicotine substitution therapy and bupropion, increasing the abstinence likelihood by a factor of 2.3 compared to a placebo. Recent data regarding anti-nicotine vaccines suggest that this approach might yield a comparable treatment outcome and probably even better relapse-preventing effects than conventional psychopharmacological strategies. The first anti-nicotine vaccines are expected to be approved by national authorities within the forthcoming 1-2 years.
Collapse
Affiliation(s)
- N Vasic
- Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum, Ulm, Deutschland.
| | | | | | | | | |
Collapse
|
15
|
Sturgess JE, George TP, Kennedy JL, Heinz A, Müller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict Biol 2011; 16:357-76. [PMID: 21362114 DOI: 10.1111/j.1369-1600.2010.00287.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The numerous premature deaths, medical complications and socio-economic repercussions of drug and alcohol addiction suggest that improvements in treatment strategies for addictive disorders are warranted. The use of pharmacogenetics to predict response to medication, side effects and appropriate dosages is relatively new in the field of drug addiction. However, increasing our understanding of the genetic factors influencing these processes may improve the treatment of addiction in the future. We examined the available scientific literature on pharmacogenetic advancements in the field of drug addiction with a focus on alcohol and tobacco to provide a summary of genes implicated in the effectiveness of pharmacotherapy for addiction. In addition, we reviewed pharmacogenetic research on cocaine and heroin dependence. Thus far, the most promising results were obtained for polymorphisms in the OPRM1 and CYP2A6 genes, which have been effective in predicting clinical response to naltrexone in alcoholism and nicotine replacement therapy in smoking, respectively. Opinions differ as to whether pharmacogenetic testing should be implemented in the clinic at this time because clinical utility and cost-effectiveness require further investigation. However, the data summarized in this review demonstrate that pharmacogenetic factors play a role in response to addiction pharmacotherapy and have the potential to aid in the personalization of addiction treatments. Such data may lead to improved cessation rates by allowing physicians to select medications for individuals based, at least in part, on genetic factors that predispose to treatment success or failure rather than on a trial and error basis.
Collapse
Affiliation(s)
- Jessica E Sturgess
- Centre for Addiction and Mental Health, Pharmacogenetics Research Clinic, 250 College Street, Toronto, Ontario, Canada
| | | | | | | | | |
Collapse
|
16
|
WATANABE MARIAANGELICAEHARA, NUNES SANDRAODEBRECHETVARGAS, AMARANTE MARLAKARINE, GUEMBAROVSKI ROBERTALOSI, ODA JULIEMASSAYOMAEDA, DE LIMA KALILWILLIAMALVES, FUNGARO MARIAHELENAPELEGRINELLI. Genetic polymorphism of serotonin transporter 5-HTTLPR: involvement in smoking behaviour. J Genet 2011; 90:179-85. [DOI: 10.1007/s12041-011-0037-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
17
|
Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MFG, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res 2011; 13:982-8. [PMID: 21690317 DOI: 10.1093/ntr/ntr106] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
INTRODUCTION The rs1051730 genetic variant within the CHRNA5-A3-B4 gene cluster is associated with heaviness of smoking and has recently been reported to be associated with likelihood of stopping smoking. We investigated the potential association of rs1051730 genotype with reduced likelihood of smoking cessation in 2 cohorts of treatment-seeking smokers in primary care in the United Kingdom. METHODS Data were drawn from 2 clinical trials on which DNA was available. One sample was a randomized placebo-controlled trial of nicotine transdermal patch and the other sample an open-label trial where all participants received nicotine transdermal patch. Smoking status was biochemically verified. Logistic regression was used to assess evidence for association in each sample, and data were combined within a meta-analysis. RESULTS There was evidence of association of rs1051730 genotype with short-term (4-week) cessation in our open-label trial sample but not our placebo-controlled trial sample. When combined in a meta-analysis, this effect remained. There was no evidence of association at later follow-up intervals. Adjustment for cigarette consumption and tobacco dependence did not alter these results substantially. CONCLUSIONS Our data, taken together with previous recent studies, provide some support for a weak association between this variant and short-term smoking cessation in treatment-seeking smokers, which does not seem to operate only among those receiving nicotine replacement therapy. Moreover, the rs1051730 variant may not merely operate as a marker for dependence or heaviness of smoking.
Collapse
Affiliation(s)
- Marcus R Munafò
- School of Experimental Psychology, University of Bristol, Bristol, UK.
| | | | | | | | | | | |
Collapse
|
18
|
David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MFG, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials. Nicotine Tob Res 2011; 13:157-67. [PMID: 21330274 PMCID: PMC3107615 DOI: 10.1093/ntr/ntq246] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2010] [Accepted: 12/14/2010] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Cigarette smoking remains the leading cause of preventable death worldwide. However, the efficacy of available first-line therapies remains low, particularly in primary care practice where most smokers seek and receive treatment. These observations reinforce the notion that 'one size fits all' smoking cessation therapies may not be optimal. Therefore, a translational research effort was launched by the Imperial Cancer Research Fund (later Cancer Research UK) General Practice Research Group, who led a decade-long research enterprise that examined the influence of pharmacological hypothesis-driven research into genetic influences on drug response for smoking cessation with transdermal nicotine replacement therapy in general practice. METHODS New and previously published smoking cessation genetic association results of 30 candidate gene polymorphisms genotyped for participants in two transdermal nicotine replacement clinical trials based in UK general practices, which employed an intention to analyze approach. RESULTS By this high bar, one of the polymorphisms (COMT rs4680) was robust to correction for multiple comparisons. Moreover, future research directions are outlined; and lessons learned as well as best-practice models for designing, analyzing, and translating results into clinical practice are proposed. CONCLUSIONS The results and lessons learned from this general practice-based pharmacogenetic research programme provide transportable insights at the transition to the second generation of pharmacogenetic and genomic investigations of smoking cessation and its translation to primary care.
Collapse
Affiliation(s)
- Sean P David
- Center for Education and Research in Family and Community Medicine, 1215 Welch Road, Modular G, Stanford University School of Medicine, Stanford, CA 94305, USA.
| | | | | | | | | | | |
Collapse
|
19
|
Wang J, Li MD. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 2010; 35:702-19. [PMID: 19890259 PMCID: PMC2814000 DOI: 10.1038/npp.2009.178] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Twin and family studies reveal a significant genetic contribution to the risk of smoking initiation and progression (SI/P), nicotine dependence (ND), and smoking cessation (SC). Further, numerous genes have been implicated in these smoking-related behaviors, especially for ND. However, no study has presented a comprehensive and systematic view of the genetic factors associated with these important smoking-related phenotypes. By reviewing the literature on these behaviors, we identified 16, 99, and 75 genes that have been associated with SI/P, ND, and SC, respectively. We then determined whether these genes were enriched in pathways important in the neuronal and brain functions underlying addiction. We identified 9, 21, and 13 pathways enriched in the genes associated with SI/P, ND, and SC, respectively. Among these pathways, four were common to all of the three phenotypes, that is, calcium signaling, cAMP-mediated signaling, dopamine receptor signaling, and G-protein-coupled receptor signaling. Further, we found that serotonin receptor signaling and tryptophan metabolism pathways were shared by SI/P and ND, tight junction signaling pathway was shared by SI/P and SC, and gap junction, neurotrophin/TRK signaling, synaptic long-term potentiation, and tyrosine metabolism were shared between ND and SC. Together, these findings show significant genetic overlap among these three related phenotypes. Although identification of susceptibility genes for smoking-related behaviors is still in an early stage, the approach used in this study has the potential to overcome the hurdles caused by factors such as genetic heterogeneity and small sample size, and thus should yield greater insights into the genetic mechanisms underlying these complex phenotypes.
Collapse
Affiliation(s)
- Ju Wang
- Section of Neurobiology, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA
| | - Ming D Li
- Section of Neurobiology, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA,Section of Neurobiology, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, 1670 Discovery Drive, Suite 110, Charlottesville, VA 22911, USA. Tel: +434 243 0566; Fax: +434 973 7031; E-mail:
| |
Collapse
|
20
|
Kortmann GL, Dobler CJ, Bizarro L, Bau CHD. Pharmacogenetics of smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:17-28. [PMID: 19475569 DOI: 10.1002/ajmg.b.30978] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Nicotine dependence is a major health problem, with a large amount of smoking-related premature deaths and disabilities. The dependence mechanism of nicotine is especially complex and is under strong genetic influence. Smoking cessation is associated with substantial health benefits. Evidence from animal and human studies suggests that genetic polymorphisms influencing pharmacokinetics and pharmacodynamics of nicotine may have great potential for aiding smoking treatment. There are more than 30 association studies and one genome-wide association study (GWAS) between genetic polymorphisms and smoking cessation following nicotine replacement therapy (NRT) and/or bupropion therapy. However, only a few candidate genes or regions were analyzed more than twice and even these genes require additional investigations in different therapeutic schemes. There are a growing number of new pharmacologic options that have not been pharmacogenetically assessed according to published literature. In addition, molecular genetics studies are needed to assess the functional mechanisms of some putative association results. Taken together, the preliminary findings are promising but raise the need for new studies with adequate sample sizes and adjustment for several potential confounding factors frequently neglected, such as comorbidity and sociodemographic factors. The current state of the art in the field encourages an optimist view that personalized treatment approaches may become possible. However, the current scientific evidence still does not support the use of pharmacogenetic tests in routine smoking cessation therapy.
Collapse
Affiliation(s)
- Gustavo L Kortmann
- Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | | | | | | |
Collapse
|
21
|
Schnoll RA, Patterson F. Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. Drug Alcohol Depend 2009; 104 Suppl 1:S94-9. [PMID: 19135319 PMCID: PMC2810256 DOI: 10.1016/j.drugalcdep.2008.11.012] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2008] [Revised: 09/03/2008] [Accepted: 11/20/2008] [Indexed: 11/24/2022]
Abstract
Approximately one-quarter of smokers who use treatments for nicotine dependence are able to achieve cessation. However, there is evidence that women do not respond as well to nicotine replacement therapy (NRT) and, perhaps, to bupropion, compared to men. In this contribution to the Special Issue of Drug and Alcohol Dependence concerning Women and Smoking, we begin with a brief overview of data supporting the role of sex in influencing response to NRT and bupropion. Next, we summarize the results of pharmacogenetic smoking cessation clinical trials which assessed sex as a moderator as well. A relatively small number of pharmacogenetic studies of nicotine dependence treatments have been conducted and five studies reported sex effects in these trials. Of these trials, sex moderated the association of genetic variation in drug pharmacokinetics or pharmacodynamics and treatment response. We conclude this paper with a summary and a brief discussion of the major caveats of this literature and priorities for future research.
Collapse
Affiliation(s)
- Robert A. Schnoll
- Corresponding Author/Requests for Reprints: Robert A. Schnoll, Ph.D., Transdisciplinary Tobacco Use Research Center, 3535 Market Street, Suite 4100, University of Pennsylvania, Philadelphia PA, 19104; Phone: 215-746-7143; Fax: 215-746-7140;
| | | |
Collapse
|
22
|
Munafò MR, Johnstone EC, Murphy MFG, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob Res 2009; 11:404-7. [PMID: 19273465 DOI: 10.1093/ntr/ntp007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
INTRODUCTION We previously reported evidence that the T allele of the dopamine type-2 receptor (DRD2) rs1800497 polymorphism is associated with improved response to nicotine replacement therapy (NRT) relative to placebo and that this association may only be present in females. However, evidence of the poor replication validity of genetic association studies is growing, particularly among those that report subgroup analyses. We therefore attempted to replicate our previous finding of an association between the DRD2 rs1800497 genotype and response to NRT in a new, larger cohort, with greater statistical power. METHODS Participants were randomly assigned to one of two levels of smoking cessation behavioral support (usual care vs. weekly support). All participants received 8 weeks of 15-mg NRT transdermal patch. RESULTS The presence of one or more T alleles was associated with a slightly but not significantly lower likelihood of abstinence at 3 and 6 months. We found evidence of a genotype x sex interaction effect. However, stratified analyses indicated a main effect of genotype opposite to the effect reported previously, with females carrying one or more copies of the T allele less likely to be abstinent. DISCUSSION Our results do not support an association between the DRD2 rs1800497 (Taq1A) polymorphism and response to NRT, contrary to our previous study.
Collapse
Affiliation(s)
- Marcus R Munafò
- Department of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol BS8 1TU, UK.
| | | | | | | |
Collapse
|
23
|
Abstract
Genetic variation may influence initial sensitivity to nicotine (i.e. during early tobacco exposure), perhaps helping to explain differential vulnerability to nicotine dependence. This study explored associations of functional candidate gene polymorphisms with initial sensitivity to nicotine in 101 young adult nonsmokers of European ancestry. Nicotine (0, 5, 10 microg/kg) was administered through nasal spray followed by mood, nicotine reward (e.g. 'liking') and perception (e.g. 'feel effects') measures, physiological responses, sensory processing (prepulse inhibition of startle), and performance tasks. Nicotine reinforcement was assessed in a separate session using a nicotine versus placebo spray choice procedure. For the dopamine D4 receptor [DRD4 variable number of tandem repeats (VNTR)], presence of the 7-repeat allele was associated with greater aversive responses to nicotine (decreases in 'vigor', positive affect, and rapid information processing; increased cortisol) and reduced nicotine choice. Individuals with at least one DRD4 7-repeat allele also reported increased 'feel effects' and greater startle response, but in men only. Other genetic associations were also observed in men but not women, such as greater 'feel effects' and anger, and reduced fatigue, in the dopamine D2 receptor (DRD2 C957T single nucleotide polymorphism) TT versus CT or CC genotypes. Very few or no significant associations were seen for the DRD2/ANKK1 TaqIA polymorphism, the serotonin transporter promoter VNTR or 5HTTLPR (SLC6A4), the dopamine transporter 3' VNTR (SLC6A3), and the mu opioid receptor A118G single nucleotide polymorphism (mu opioid receptor polymorphism 1). Although these results are preliminary, this study is the first to suggest that genetic polymorphisms related to function in the dopamine D4, and perhaps D2, receptor may modulate initial sensitivity to nicotine before the onset of dependence and may do so differentially between men and women.
Collapse
|
24
|
Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol 2008; 19:641-9. [PMID: 18690118 DOI: 10.1097/fbp.0b013e32830c367c] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Negative mood increases smoking reinforcement and risk of relapse. We explored associations of gene variants in the dopamine, opioid, and serotonin pathways with smoking reward ('liking') and reinforcement (latency to first puff and total puffs) as a function of negative mood and expected versus actual nicotine content of the cigarette. Smokers of European ancestry (n=72) were randomized to one of four groups in a 2x2 balanced placebo design, corresponding with manipulation of actual (0.6 vs. 0.05 mg) and expected (told nicotine and told denicotinized) nicotine 'dose' in cigarettes during each of two sessions (negative vs. positive mood induction). Following mood induction and expectancy instructions, they sampled and rated the assigned cigarette, and then smoked additional cigarettes ad lib during continued mood induction. The increase in smoking amount owing to negative mood was associated with: dopamine D2 receptor (DRD2) C957T (CC>TT or CT), SLC6A3 (presence of 9 repeat>absence of 9), and among those given a nicotine cigarette, DRD4 (presence of 7 repeat>absence of 7) and DRD2/ANKK1 TaqIA (TT or CT>CC). SLC6A3, and DRD2/ANKK1 TaqIA were also associated with smoking reward and smoking latency. OPRM1 (AA>AG or GG) was associated with smoking reward, but SLC6A4 variable number tandem repeat was unrelated to any of these measures. These results warrant replication but provide the first evidence for genetic associations with the acute increase in smoking reward and reinforcement owing to negative mood.
Collapse
|
25
|
David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, Munafò MR. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend 2008; 98:77-85. [PMID: 18562131 PMCID: PMC4439462 DOI: 10.1016/j.drugalcdep.2008.04.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2008] [Revised: 04/20/2008] [Accepted: 04/23/2008] [Indexed: 11/24/2022]
Abstract
The serotonin pathway has been implicated in nicotine dependence and may influence smoking cessation. Therefore, 792 cigarette smokers from the Patch in Practice trial were genotyped for the tryptophan hydroxylase (TPH1 A779C), serotonin transporter (SLC6A45-HTTLPR), and 5-HT1A (HTR1A C-1019G) polymorphisms. Cox regression analysis did not demonstrate significant effects of any of the three genotypes on relapse to smoking: TPH1 (Reference AA; AC: hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.78, 1.24, p=0.90; CC: HR 0.93, 95% CI 0.73, 1.18, p=0.55); 5-HTTLPR (Reference LL; SL: HR 1.01, 95% CI 0.85, 1.20, p=0.90; SS: HR 1.13, 95% CI 0.91, 1.39, p=0.27); HTR1A (Reference CC; CG: HR 1.04, 95% CI 0.86, 1.25, p=0.70; GG: HR 1.01, 95% CI 0.82, 1.24, p=0.93). Moreover, pooled analyses of data from all three extant pharmacogenetic NRT trials (N=1398) found no significant effect of 5-HTTLPR genotype on continuous abstinence at 12-week (Reference LL; SL: odds ratio (OR)=1.25, 95% CI 0.89, 1.74, p=0.19; SS: OR=1.31, 95% CI 0.86, 1.98, p=0.21) or 26-week follow-up (Reference LL; SL: OR=0.93, 95% CI 0.64, 1.33, p=0.68; SS: OR=1.00, 95% CI 0.63, 1.58, p=1.00). These data do not support a statistically or clinically significant moderating effect of these specific 5-HT pathway genetic variants on smoking cessation. However, the possibility remains that other variants in these or other 5-HT genes may influence NRT efficacy for smoking cessation in treatment seeking smokers.
Collapse
Affiliation(s)
- Sean P. David
- Department of Family Medicine, Center for Primary Care & Prevention, The Warren Alpert Medical School of Brown University, 111 Brewster Street, Pawtucket, RI 02806, USA,Corresponding author at: Brown University Center for Primary Care & Prevention, 111 Brewster Street, Pawtucket, RI 02860, USA. Tel.: +1 401 729 2071; fax: +1 401 729 2494. (S.P. David)
| | - Elaine C. Johnstone
- Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Old Road Campus, Oxford OX3 7DQ, UK
| | - Michael F.G. Murphy
- Department of Paediatrics, Childhood Cancer Research Group, University of Oxford, 57 Woodstock Road, Oxford OX2 6HJ, UK
| | - Paul Aveyard
- Department of Primary Care and General Practice, University of Birmingham, Edgbaston B15 2TT, UK
| | - Boliang Guo
- Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT, UK
| | - Caryn Lerman
- Department of Psychiatry, Tobacco Use Research Center, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19194, USA
| | - Marcus R. Munafò
- Department of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol BS8 1TU, UK
| |
Collapse
|
26
|
Welton NJ, Johnstone EC, David SP, Munafò MR. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 2008; 10:231-40. [PMID: 18188764 DOI: 10.1080/14622200701767761] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
We conducted a cost-effectiveness analysis of genetic testing for smoking cessation, based on data available from the published pharmacogenetic studies of nicotine replacement therapy and bupropion, and a previous cost-effectiveness analysis of smoking cessation treatments. We use multiparameter evidence synthesis methods to combine evidence on cessation by genotype with evidence on cessation irrespective of genotype (which can be written as a function of genotype-specific parameters). Our intention was to explore the most cost-effective approach to prescribing smoking cessation pharmacotherapy, given the hypothetical availability of a test based on a single-gene variant that has been reported to predict treatment response. We considered four types of treatment: nicotine replacement therapy (NRT) pharmacotherapy, bupropion SR pharmacotherapy, combination NRT and bupropion, and standard care as the control. Two scenarios were investigated, one in which the control represented brief advice and the other in which the control represented individual counseling. Strategies that either do not test for dopamine D2 receptor (DRD2) genotype (each individual receives the same treatment), or do test for DRD2 genotype (treatment allocated according to genotype), were evaluated. Our results indicated that the most cost-effective strategy in our hypothetical example of a single-gene test to aid prescription of smoking cessation pharmacotherapy is to prescribe both NRT and bupropion regardless of genotype, as a first-line treatment for smoking cessation. We conclude that it should not be assumed that genetic tailoring will necessarily be more cost-effective than applying the current "one-size-fits-all" model of pharmacotherapy for smoking cessation. In addition, single-gene tests are unlikely to be cost-effective, partly because the predictive value of these tests is likely to be modest.
Collapse
Affiliation(s)
- Nicky J Welton
- Primary Care, Department, Community Based Medicine, University of Bristol, Bristol, UK.
| | | | | | | |
Collapse
|
27
|
Abstract
AIMS Attempts to further our understanding of the determinants of cigarette smoking, tobacco addiction and related behaviours have included the dissection of genetic influences on these phenotypes. This review summarizes the current state of evidence from both twin and adoption studies and molecular genetic studies. We also review future research horizons and the direction which studies of this kind are likely to take in the near future. FINDINGS There is consistent evidence from twin and adoption studies that genetic factors play a role in the aetiology of cigarette smoking. Nevertheless, despite a large number of candidate gene studies, and a smaller number of linkage studies, few reported associations and chromosomal regions of interest have proved to replicate reliably. This is due most probably to the small effects of individual loci on complex behaviours such as smoking. CONCLUSIONS Future research is likely to include the study of gene x environment interactions (including gene x treatment interactions, which offer the prospect of genetically tailored smoking cessation treatment) and the use of more sophisticated smoking-related phenotypes, such as longitudinal smoking trajectories, and intermediate phenotypes which use technologies such as neuroimaging and other laboratory and biobehavioural measures.
Collapse
Affiliation(s)
- Marcus R Munafò
- Department of Experimental Psychology, University of Bristol, Bristol, UK.
| | | |
Collapse
|
28
|
Abstract
OBJECTIVES We attempted to extend a previous finding of an association of COMT genotype with response to nicotine-replacement therapy (NRT), in a larger cohort of treatment-seeking smokers, with greater statistical power to detect possible moderating effects of sex. We also investigated the association of the COMT genotype with withdrawal and mood symptoms, to identify possible mediating mechanisms by which the COMT genotype might influence response to NRT. METHODS Participants were eligible if they were aged 18 years or older, and if they smoked 10 cigarettes per day or more; they were recruited from 26 general practice clinics in Buckinghamshire and Oxfordshire in the United Kingdom. All participants received 8 weeks of 15-mg NRT transdermal patch. Confirmation of abstinence was defined as an exhaled CO of less than 10 parts per million (ppm), or salivary cotinine concentration of less than 15 ng/ml. RESULTS Cox regression analysis indicated a significant effect of the COMT genotype on relapse into smoking (P=0.001), with shorter times to relapse being observed among the AG (Val/Met) and GG (Val/Val) genotype groups. These effects were observed both during active treatment and as soon as active treatment had ended. The effect, however, was greater, once active treatment had ended, in the subgroup of smokers who had abstained up to this point. We did not observe any evidence of a sex difference in the effect of the COMT genotype. These effects did not seem to be mediated by self-reported withdrawal or mood symptoms. CONCLUSIONS Our results indicate that the COMT genotype is associated with the likelihood of smoking cessation in smokers treated with the NRT transdermal patch. Future large-scale studies will be required to afford sufficient power to simultaneously investigate the role of multiple genetic variants in treatment responses, and the effects of potential moderating variables on these associations.
Collapse
|
29
|
"Intention to Analyze" in Pharmacogenomics Studies. Cancer Epidemiol Biomarkers Prev 2008; 17:740; author reply 740-1. [DOI: 10.1158/1055-9965.epi-07-2929] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
30
|
Munafo MR, Johnstone EC, Murphy MF, Aveyard P. "Intention to Analyze" in Pharmacogenomics Studies. Cancer Epidemiol Biomarkers Prev 2008. [DOI: 10.1158/1055-9965.epi-08-0099] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
31
|
Hall WD, Gartner CE, Carter A. The genetics of nicotine addiction liability: ethical and social policy implications. Addiction 2008; 103:350-9. [PMID: 18190673 DOI: 10.1111/j.1360-0443.2007.02070.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIM To assess the promise and risks of technological applications of genetic research on liability to develop nicotine dependence. METHODS We reviewed (i) the evidence on the genetics of nicotine dependence; (ii) the technical feasibility of using genetic information to reduce smoking uptake and increase cessation; and (iii) policy and ethical issues raised by the uses of genetic information on addiction liability. RESULTS (i) Despite evidence from twin studies that genes contribute to addiction susceptibility, research to date has not identified commonly occurring alleles that are strongly predictive of developing nicotine addiction. Nicotine addiction is likely to involve multiple alleles of small effect that interact with each other and with the environment. (ii) Population screening for susceptibility alleles is unlikely to be effective or cost-effective. Tailoring of smoking cessation treatments with genetic information is more plausible but results to date have been disappointing. Population health strategies such as increased taxation and reduced opportunities to smoke are more efficient in reducing cigarette smoking. Tobacco harm reduction policies applied to populations may also play a role in reducing tobacco-related harm. (iii) Future uses of genomic information on addiction risk will need to assess the risks of medicalising addiction (e.g. pessimism about capacity to quit) and community concerns about genetic privacy. CONCLUSIONS Nicotine genomics is a very new and underdeveloped field. On the evidence to date, its advocates would be wise to avoid extravagant claims about its preventive applications.
Collapse
Affiliation(s)
- Wayne D Hall
- School of Population Health, The University of Queensland, Queensland, Australia.
| | | | | |
Collapse
|
32
|
O'Gara C, Knight J, Stapleton J, Luty J, Neale B, Nash M, Heuzo-Diaz P, Hoda F, Cohen S, Sutherland G, Collier D, Sham P, Ball D, McGuffin P, Craig I. Association of the serotonin transporter gene, neuroticism and smoking behaviours. J Hum Genet 2008; 53:239-246. [PMID: 18188666 DOI: 10.1007/s10038-007-0243-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2007] [Accepted: 12/15/2007] [Indexed: 11/26/2022]
Abstract
Cigarette consumption and smoking cessation are influenced in part by genes. Personality traits have also been implicated in the aetiology of smoking. Neuroticism, a personality trait with a heritable component, correlates well with anxiety and depression, increasing the risk of being a smoker and decreasing the chance of smoking cessation. Several prior studies in non-British populations have given conflicting results as to whether some genetic polymorphisms affect the relationship between smoking and neuroticism. This study investigated the influence of serotonin transporter (5HTTLPR) genotypes on a composite measure of neuroticism and cigarette consumption/smoking cessation in a British population. Although neuroticism was significantly associated with cigarette consumption and smoking cessation, genotype did not affect this relationship. Our results do not support initial interest in utilising 5HTTLPR genotypes in combination with neuroticism ratings for predicting outcome in smoking cessation clinical settings.
Collapse
Affiliation(s)
- Colin O'Gara
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK.
- St. John of God Hospital, Stillorgan, Co Dublin, Ireland.
| | - Jo Knight
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - John Stapleton
- Tobacco Research Unit, National Addiction Centre, Institute of Psychiatry, London, UK
| | - Jason Luty
- South Essex Partnership NHS Trust, The Taylor Centre, Queensway House, Essex Street, Southend on Sea, Essex, SS4 1RB, UK
| | - Ben Neale
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Matt Nash
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Patricia Heuzo-Diaz
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Farzana Hoda
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Sarah Cohen
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Gay Sutherland
- Tobacco Research Unit, National Addiction Centre, Institute of Psychiatry, London, UK
| | - David Collier
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Pak Sham
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - David Ball
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Peter McGuffin
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| | - Ian Craig
- MRC Social Genetic and Developmental Psychiatry Research Centre, King's College London, Institute of Psychiatry, London, UK
| |
Collapse
|
33
|
Lerman CE, Schnoll RA, Munafò MR. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 2007; 33:S398-405. [PMID: 18021915 PMCID: PMC2170888 DOI: 10.1016/j.amepre.2007.09.006] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2007] [Revised: 08/03/2007] [Accepted: 09/17/2007] [Indexed: 10/22/2022]
Abstract
This article reviews evidence supporting the potential utility of a pharmacogenetic approach to the treatment of nicotine dependence. There is substantial evidence that nicotine dependence and smoking persistence are heritable, and are determined by a complex interplay of polygenic and environmental influences. The most robust evidence for specific genetic influences on nicotine dependence is found in studies of genetic variation in nicotine-metabolizing enzymes. Data also support the role of genes in the dopamine and opioid pathways as predictors of dependence and smoking relapse; however, the evidence for genetic associations is not always consistent. Emerging data from pharmacogenetic trials of nicotine-dependence treatment are promising, suggesting that genetic profiles of smokers someday may be used by providers to choose the type, dose, and duration of treatment for individual smokers. However, additional trials including larger and more diverse populations are needed before such data can be translated to practice to reduce smoking prevalence and tobacco-related disease.
Collapse
Affiliation(s)
- Caryn E Lerman
- Transdisciplinary Tobacco Use Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
| | | | | |
Collapse
|
34
|
Abstract
Accumulating data support the role of genetic factors in smoking initiation, progression to tobacco dependence, and smoking persistence. This review summarizes current research on the heritability of tobacco use phenotypes and genetic association studies of smoking-related behaviors. Although progress has been made in genetics research on smoking behavior, many studies have methodological limitations, including insufficient samples for detecting gene-gene and gene-environment interactions and use of less refined phenotypes. Pharmacogenetic investigations also are identifying variants in drug-metabolizing enzymes, receptors, and transporters that modify therapeutic response to smoking cessation medications; however, the field is relatively new, and most findings in this area have yet to be replicated. As this research advances, it will be important to study and address practical, economic, ethical, and social barriers to the translation of genetics research on tobacco use to clinical practice.
Collapse
Affiliation(s)
- Robert A Schnoll
- Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104, USA.
| | | | | |
Collapse
|
35
|
Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 2007; 75:178-95. [PMID: 17888884 PMCID: PMC2238639 DOI: 10.1016/j.bcp.2007.08.018] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2007] [Revised: 08/13/2007] [Accepted: 08/15/2007] [Indexed: 12/22/2022]
Abstract
Nicotine dependence is substantially heritable. Several regions across the genome have been implicated in containing genes that confer liability to nicotine dependence and variation in individual genes has been associated with nicotine dependence. Smoking cessation measures are also heritable, and measured genetic variation is associated with nicotine dependence treatment efficacy. Despite significant strides in the understanding of the relative contribution of genetic and environmental factors to nicotine dependence and treatment, emergent challenges necessitate interdisciplinary coordinated effort for effective problem solving. These challenges include refinement of the nicotine dependence phenotype, better understanding of the dynamic interplay between genes and environment in nicotine dependence etiology, application and development of molecular and statistical methodology that can adequately address vast amounts of data, and continuous translational cross-talk.
Collapse
|
36
|
Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafò MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2007; 16:1065-9. [PMID: 17548664 PMCID: PMC2031911 DOI: 10.1158/1055-9965.epi-06-0936] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We investigated the association of catechol O-methyltransferase (COMT) genotype with abstinence following a smoking cessation attempt among a large cohort of smokers who attempted to quit using either the nicotine transdermal patch or placebo and were followed up over an 8-year period following their initial cessation attempt. In addition, we examined the possible moderating influence of sex on any association. The genotype x treatment interaction effect at 12-week follow-up indicated a greater benefit of active nicotine replacement treatment compared with placebo on likelihood of abstinence in the COMT Met/Met genotype group (33% versus 12%), in comparison to the Met/Val + Val/Val group (22% versus 16%). Our results indicate that COMT genotype may moderate the effect of active transdermal nicotine patch compared with placebo, with reduced relative benefit of nicotine replacement therapy in individuals with Met/Val or Val/Val genotype. Our data follow an emerging pattern of results suggesting that genetic variation in the dopamine pathway may provide a future basis for tailored smoking cessation therapies, but indicate that different genes influencing various components of this pathway may have different effects on response to smoking cessation pharmacotherapy.
Collapse
Affiliation(s)
- Elaine C. Johnstone
- Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
| | - Katherine M. Elliot
- Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
| | - Sean P. David
- The Warren Alpert Medical School of Brown Medical School and Memorial Hospital of Rhode Island, Rhode Island
| | - Michael F.G. Murphy
- Childhood Cancer Research Group, University of Oxford, Oxford, United Kingdom
| | - Robert T. Walton
- Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
- Medical Research Council Laboratories, Banjul, Gambia
| | - Marcus R. Munafò
- Department of Experimental Psychology, University of Bristol, Bristol, United Kingdom
| |
Collapse
|
37
|
David SP, Munafò MR, Murphy MFG, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res 2007; 9:225-31. [PMID: 17365753 PMCID: PMC2031912 DOI: 10.1080/14622200601078566] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
In this follow-up of a randomized placebo-controlled clinical trial of nicotine replacement transdermal patch for smoking cessation, 741 smokers of European ancestry who were randomized to receive active patch or placebo patch were genotyped for the serotonin transporter gene-linked polymorphic region. The study setting was a primary care research network in Oxfordshire, United Kingdom. The primary outcome measures were biochemically verified sustained abstinence from cigarette smoking at end of treatment and 24-week follow-up. The main effect of genotype was not associated with sustained abstinence from smoking at either end of treatment (SL: p=.33; SS: p=.81) or 24-week follow-up (SL: p=.05; SS: p=.21), and we found no evidence for a genotypextreatment interaction effect. In summary, despite the theoretically important contribution of serotonin neurotransmission to smoking cessation, the serotonin transporter gene was not associated with treatment response to nicotine patch for smoking cessation in this primary care-based trial.
Collapse
Affiliation(s)
- Sean P David
- Center for Primary Care & Prevention, Brown Medical School/Memorial Hospital of Rhode Island, Pawtucket, RI 02960, USA.
| | | | | | | | | |
Collapse
|
38
|
|
39
|
Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. THE PHARMACOGENOMICS JOURNAL 2007; 7:81-98. [PMID: 17224913 DOI: 10.1038/sj.tpj.6500436] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Cigarette smoking increases the risk of numerous health problems, including cancer, cardiovascular and pulmonary disorders, making smoking the leading cause of preventable death in the world. Nicotine is primarily responsible for the highly addictive properties of cigarettes. Although the majority of smokers express a desire to quit, few are successful in doing so. Twin and family studies have indicated substantial genetic contributions to smoking behaviors. One major research focus has been to elucidate the specific genes involved; this has been accomplished primarily through genome-wide linkage analyses and candidate gene association studies. Much attention has focused on genes involved in the neurotransmitter pathways for the brain reward system and genes altering nicotine metabolism. This paper reviews the current state of knowledge for genetic factors implicated in smoking behaviors, and examines how genetic variations may affect therapeutic outcomes for drugs used to assist smoking cessation.
Collapse
Affiliation(s)
- M K Ho
- Centre for Addiction and Mental Health, Department of Pharmacology, University of Toronto, Toronto, Canada
| | | |
Collapse
|
40
|
Munafò MR, Elliot KM, Murphy MFG, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation. THE PHARMACOGENOMICS JOURNAL 2007; 7:353-61. [PMID: 17224915 DOI: 10.1038/sj.tpj.6500432] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We investigated the association of the OPRM1 genotype with long-term smoking cessation and change in body mass index (BMI) following a smoking cessation attempt among smokers who attempted to quit using the nicotine replacement therapy (NRT) patch or placebo in a randomized controlled trial, and were followed-up over an 8-year period following their initial cessation attempt. We also investigated possible sex differences in these relationships, given evidence for sex differences in smoking cessation and central opioid mechanisms, as well as some evidence for sex differences in response to NRT. Our results indicate that OPRM1 genotype may moderate the effect of transdermal nicotine patch compared to placebo during active treatment, with a benefit of active NRT treatment evident in the OPRM1 AA genotype group only and those carrying one or more copies of the G allele demonstrating no benefit of active NRT versus placebo patch. Our results also indicate a sex difference in change in BMI at 8-year follow-up following a smoking cessation attempt, with ex-smokers demonstrating an increase in BMI, and this increase being greater in female subjects than in male subjects. We did not observe any association of OPRM1 genotype with change in BMI, although there was a trend for genotype to influence the observed sex difference in change in BMI over time. Future studies should attempt to replicate these findings, and investigate the relationship between both short- and long-term weight gain and smoking cessation and investigate possible mechanisms that may underlie these processes. Future studies should also investigate the role of OPRM1 genotype and smoking cessation on other appetitive and reward behaviours such as alcohol consumption.
Collapse
Affiliation(s)
- M R Munafò
- Department of Experimental Psychology, University of Bristol, Bristol, UK.
| | | | | | | | | |
Collapse
|